Alebund’s AP308 Gets FDA IND Clearance for IgA Nephropathy
Shanghai, China, September 8, 2026 Alebund Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared...
renal disease
Advertisement
Alebund Pharmaceuticals Gains China NMPA NDA Acceptance
SHANGHAI, August 7, 2026 Alebund Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) has formally accepted for review...
Dimerix Secures Funding to Advance DMX-200 Phase 3 Trial
MELBOURNE, Australia, July 17, 2026 Dimerix Limited has secured an initial AU$10 million non-dilutive loan facility to strengthen its...
Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
CSPC Pharma Secures Up to $1.77B AstraZeneca siRNA Deal
HONG KONG, July 2, 2026 CSPC Pharmaceutical Group Limited has announced a strategic collaboration, option and license agreement with...
Advertisements
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
Novartis Fabhalta® Slows Kidney Function Decline in Phase III IgAN Study
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
Advertisement
